Oral CHK1 inhibitor BBI-355 allows flexibility of dose and schedule with demonstration of monotherapy and combinational antitumor activity in extrachromosomal DNA (ecDNA) driven preclinical models

被引：0
|
作者：
Hansen, Ryan J.
Steffy, Auzon
Plum, Joshua
Ardeshiri, Ardalan
Tse, Edison
Garcia, Salvador
Norman, Ben
Moininazeri, Jafar
Pferdekamper, AnneMarie
Holmes, Evan
Liao, Debbie
Elsdon, Rachelle
Lange, Joshua
Pinkerton, Anthony
Apuy, Julius
Chowdhry, Sudhir
Hassig, Christian
Kasibhatla, Shailaja
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-613
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
613
引用
收藏
页数：2
相关论文
共 1 条
  • [1] Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA)
    Drilon, A.
    Rivera, I. I. Rodriguez
    Spira, A. I.
    Sharma, M. R.
    Hansen, R.
    Chowdhry, S.
    Kasibhatla, S.
    Tewari, A.
    Weymer, S.
    Wagner, K.
    Yap, T. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S477 - S477
1